Skip to content
Open access

Survival Outcomes in Transthyretin Cardiac Amyloidosis in the Tafamidis Era: Real-World Evidence from Greece

Oct 2026 · Diagnostics · Vol 16 · 0 citations · 28 references
Medicine

Abstract

Background: Diagnoses of transthyretin amyloid cardiomyopathy (ATTR-CM) have increased in recent years, with a growing proportion of patients being identified at earlier disease stages. However, temporal trends in ATTR-CM diagnosis and survival during the tafamidis era in the Greek population remain largely unknown. Methods: This retrospective study included 75 patients with ATTR-CM treated with tafamidis. Baseline demographic, clinical, laboratory, and echocardiographic characteristics were assessed, and survival outcomes were subsequently evaluated. Results: Among 75 tafamidis-treated patients, 14 deaths (19%) occurred during a median follow-up of 20 months [IQR 10.0–30.5] with an estimated 30-month survival of 75%. Kaplan–Meier analysis demonstrated significantly poorer survival among patients aged ≥80 years (log-rank p = 0.013), those with NYHA class III–IV (log-rank p = 0.018), and across progressively more advanced NAC stages I–III (global log-rank p < 0.001). In contrast, survival did not differ significantly according to LVEF <50% versus ≥50% (log-rank p = 0.863) or maximal wall thickness ≥15 mm versus <15 mm (log-rank p = 0.801). After Holm correction across five comparisons, only NAC stage remained statistically significant (adjusted p < 0.001). Conclusions: In this real-world Greek cohort of patients with ATTR-CM treated with tafamidis, the estimated 30-month all-cause mortality was 25% and more advanced NAC stage was associated with poorer survival.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.